Literature DB >> 29235054

Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey.

Chao-Feng Chang1, Yu-Chen Tseng1, Hsin-Hung Huang1, Yu-Lueng Shih1, Tsai-Yuan Hsieh1, Hsuan-Hwai Lin2.   

Abstract

Pancreatic cancer is difficult to diagnose in an early stage, and has the highest mortality of all types of cancer. Obesity, high body mass index, and increased abdominal girth are established risk factors. Some studies have postulated that there is a correlation between organ steatosis and pancreatic cancer. This study aims to explore whether nonalcoholic fatty liver disease (NAFLD) is a risk factor and a prognostic factor for pancreatic cancer. The study enrolled 557 patients (143 with and 414 without pancreatic cancer) who were diagnosed between January 2009 and December 2013. We reviewed the abdominal computed tomographic scans of the patients to confirm the diagnosis of NAFLD. Clinical parameters, laboratory data, and personal information were analyzed. NAFLD is an independent risk factor for pancreatic cancer according to adjusted multivariate logistic regression analysis (OR 2.63, 95% CI 1.24-5.58, p = 0.011). The Kaplan-Meier survival curve reveals that patients without NAFLD have longer survival than patients with NAFLD (p = 0.005, log-rank test). NAFLD is positively correlated with pancreatic cancer, a result suggesting that NAFLD may increase the incidence and risk of pancreatic cancer. Patients with pancreatic cancer and NAFLD have poorer overall survival than patients without NAFLD, perhaps, because dysregulated cytokine status leads to progression of pancreatic cancer. NAFLD may be a prognostic factor for pancreatic cancer.

Entities:  

Keywords:  Abdominal fat; Computed tomography; Fatty liver; Pancreatic cancer

Mesh:

Year:  2017        PMID: 29235054     DOI: 10.1007/s11739-017-1774-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  46 in total

Review 1.  Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms.

Authors:  Paige M Bracci
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  The risk of cancer in users of statins.

Authors:  Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

3.  Cachexia in pancreatic cancer: new treatment options and measures of success.

Authors:  Kenneth C H Fearon; Vickie E Baracos
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease.

Authors:  Erwin-Jan M van Geenen; Mark M Smits; Tim C M A Schreuder; Donald L van der Peet; Elisabeth Bloemena; Chris J J Mulder
Journal:  Pancreas       Date:  2010-11       Impact factor: 3.327

Review 5.  The role of aspirin in cancer prevention.

Authors:  Michael J Thun; Eric J Jacobs; Carlo Patrono
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

6.  Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

7.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

Authors:  L Blais; A Desgagné; J LeLorier
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

Review 8.  Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers.

Authors:  Shouji Shimoyama
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-17       Impact factor: 3.333

9.  Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.

Authors:  M A Molina; M Sitja-Arnau; M G Lemoine; M L Frazier; F A Sinicrope
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

10.  Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer.

Authors:  Oliver Stoeltzing; Wenbiao Liu; Niels Reinmuth; Fan Fan; Alexander A Parikh; Corazon D Bucana; Douglas B Evans; Gregg L Semenza; Lee M Ellis
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

View more
  14 in total

1.  Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey: comment.

Authors:  Shih-Wei Lai
Journal:  Intern Emerg Med       Date:  2018-10-11       Impact factor: 3.397

2.  Pancreatic cancer: risk and preventive factors.

Authors:  Anna Licata; Giuseppe Montalto; Maurizio Soresi
Journal:  Intern Emerg Med       Date:  2018-02-07       Impact factor: 3.397

3.  Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  Min-Seok Seo; Jina Yeo; In Cheol Hwang; Jae-Yong Shim
Journal:  Clin Rheumatol       Date:  2019-07-03       Impact factor: 2.980

4.  p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.

Authors:  Carolina Torres; Georgina Mancinelli; Jose Cordoba-Chacon; Navin Viswakarma; Karla Castellanos; Sam Grimaldo; Sandeep Kumar; Daniel Principe; Matthew J Dorman; Ronald McKinney; Emilio Hirsch; David Dawson; Hidayatullah G Munshi; Ajay Rana; Paul J Grippo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-02       Impact factor: 11.205

Review 5.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

6.  Prediction of Pancreatic Cancer in Diabetes Patients with Worsening Glycemic Control.

Authors:  Christie Y Jeon; Sungjin Kim; Yu-Chen Lin; Harvey A Risch; Mark O Goodarzi; Teryl K Nuckols; Stephen J Freedland; Stephen J Pandol; Joseph R Pisegna
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-02       Impact factor: 4.090

7.  Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.

Authors:  Shou-Sheng Liu; Xue-Feng Ma; Jie Zhao; Shui-Xian Du; Jie Zhang; Meng-Zhen Dong; Yong-Ning Xin
Journal:  Lipids Health Dis       Date:  2020-05-31       Impact factor: 3.876

8.  The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers.

Authors:  Nicolette Veracruz; Bilal Hameed; Sammy Saab; Robert J Wong
Journal:  J Clin Exp Hepatol       Date:  2020-05-20

Review 9.  Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.

Authors:  Guido Eibl; Enrique Rozengurt
Journal:  Cancer Metastasis Rev       Date:  2021-06-17       Impact factor: 9.237

Review 10.  Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs.

Authors:  Wataru Tomeno; Kento Imajo; Takuya Takayanagi; Yu Ebisawa; Kosuke Seita; Tsuneyuki Takimoto; Kanami Honda; Takashi Kobayashi; Asako Nogami; Takayuki Kato; Yasushi Honda; Takaomi Kessoku; Yuji Ogawa; Hiroyuki Kirikoshi; Yasunari Sakamoto; Masato Yoneda; Satoru Saito; Atsushi Nakajima
Journal:  Diagnostics (Basel)       Date:  2020-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.